Galatea Bio
Miami Lakes, US · Founded 2021 · Delaware corporation · 14 known investors
Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.
Also known as Galatea Bio Inc.
Founders & leadership
Galatea Bio was founded in 2021 by Carlos D. Bustamante.
Board
Investors · 14
Also in the syndicate · 5
Reported raises · per SEC filings
Form D private placements$3.7M disclosed across 1 of 2 rounds · 2024–2025
▶$3.7MraisedSep 2024 · 4 investors · Other Health CareRule 506(b)
- Nicholas KatsanisDirector
- Carlos D. BustamanteExecutive Officer, Director
- Muzammil MansuriDirector
- Arthur PolkExecutive Officer
- Wale AyeniDirector
- Cindy CheungDirector
- Alexander IoannidisDirector
- Mohit KaushalDirector
- Offering amount
- $12M
- Amount sold
- $3.7M
- Minimum investment
- $1
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Galatea Bio is a US biotechnology company focused on genomic research and clinical genetic testing, combining large-scale sequencing with AI-driven data analytics. It operates a laboratory in Miami Lakes, Florida, offering full-service sequencing, molecular diagnostics, and genomic analysis. The company's central asset is a genomic database and biobank oriented toward populations historically underrepresented in genetics research, including Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander communities across Latin America and diaspora populations.
The company is expanding its Biobank of the Americas into the Galatea Global Biobank, with a stated goal of sequencing 10 million participants worldwide, emphasizing people of non-European ancestry. Whole-genome and whole-exome sequence data are paired with longitudinal clinical records and real-world health evidence to build reference populations intended to support biomarker and drug target discovery, genetic risk analysis for Mendelian and complex diseases, clinical trial optimization, and clinical diagnostic development.
Products include StrataRisk, a polygenic risk score software platform launched in early 2025 that assesses polygenic contribution to common diseases such as cardiovascular disease, metabolic disorders, and cancer susceptibility.
Founding story
Galatea Bio was founded in 2021 by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis, with a stated focus on populations historically underrepresented in genetics research.
Business model
Galatea Bio combines laboratory services (sequencing and molecular diagnostics) with a proprietary genomic database and software platforms licensed or delivered through partnerships with health systems, research institutions, and genomics software companies.
Traction
The company has strategic partnerships and intellectual property licensing arrangements with Stanford University and the Chan Zuckerberg Initiative, collaborations with health systems including Baptist Health-South Florida, a 2024 agreement with DNAnexus, and a 2025 product partnership with Fabric Genomics. It raised $25 million in a private financing round announced in March 2025.
Latest developments
In March 2025 Galatea Bio announced a $25 million financing, appointed Jeff Gulcher as Chief Medical Officer and Francisco M. De La Vega as Chief Technology Officer, and added Muzammil Mansuri and Wale Ayeni to its board. In June 2025 it announced a partnership with Fabric Genomics, a GeneDx subsidiary, whose first deliverable is a cardiovascular gene panel based on American Heart Association recommendations paired with polygenic risk scores, with a hereditary cancer panel covering breast, colorectal, and prostate cancers to follow.
▸Full profile — market position, technology, go-to-market, geography
Market position
Galatea Bio positions itself against the predominance of European-ancestry data in existing genomic research, aiming to build what it describes as the largest inclusive biobank in the Americas and, subsequently, a global biobank.
The company's biobank is deliberately weighted toward non-European ancestry participants, which it uses to address the reduced accuracy of polygenic risk scores in those populations, and it combines rare-variant panel testing with polygenic risk scoring rather than relying on either method alone.
Technology
The company performs whole-genome and whole-exome sequencing and links the resulting data with longitudinal health records and real-world evidence. Its StrataRisk platform applies machine learning to polygenic risk scoring, matching each individual to 1,000 genetically similar individuals in its biobank in order to compute scores that hold across ancestries. Analysis is extended to multimodal data and AI-driven applications; genomic datasets are managed on DNAnexus' Precision Health Data Cloud. Panels developed with Fabric Genomics were validated with Broad Clinical Labs using its Blended Genome-Exome sequencing approach, which combines low-pass whole genome sequencing with deeper-coverage whole exome sequencing.
Go-to-market
Growth is driven by partnerships and licensing deals with academic institutions, health systems, and genomics software firms, alongside direct provision of sequencing and diagnostic services from its Miami Lakes laboratory.
Researchers, pharmaceutical and biotech drug developers, clinical laboratories, health systems, and clinicians ordering genetic testing, as well as the patient communities contributing to the biobank.
Geography
Headquartered in Miami Lakes / Miami, Florida, with a laboratory there; it serves clients in the United States and targets participants across Latin America, diaspora communities, and, per investor commentary, African populations.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 5
by search overlap
Companies competing with Galatea Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 6
launches, deals, and filingsGalatea Bio and Fabric Genomics (a GeneDx subsidiary) partnered to combine rare variant gene panel testing with Galatea's StrataRisk polygenic risk scores. The first product is a cardiovascular gene panel based on American Heart Association recommendations, followed by a hereditary cancer panel for breast, colorectal and prostate cancers; panels were developed and validated with Broad Clinical Labs using Blended Genome-Exome sequencing.
Galatea Bio announced a $25 million private financing round to expand sequencing, AI-powered genomic analysis, and its biobank, with participation from F-Prime, Helios Digital Ventures, Digitalis Ventures, CEI Ventures, AME Cloud, Alexandria, Founders Collective, the Stanford President's Fund, and HBM Genomics.
$25M source ↗
Galatea Bio appointed Jeff Gulcher as chief medical officer and Francisco M. De La Vega as chief technology officer.
Muzammil Mansuri (formerly of Sanofi, Gilead and Flagship Pioneering) and Wale Ayeni, managing partner at Helios Digital Ventures, joined Galatea Bio's board of directors.
Galatea Bio launched StrataRisk, a polygenic risk score software platform designed to assess the polygenic contribution to common diseases such as cardiovascular disease, metabolic disorders and cancer susceptibility.
In mid-2024 Galatea Bio signed an agreement to use DNAnexus' Precision Health Data Cloud to manage, analyze and broaden accessibility of genomic datasets of non-European origin.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 6
primary sources listed
- Galatea Bio Inc - Company Profile and News - Bloomberg Marketsbloomberg.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Galatea Bio do?
- Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.
- Who founded Galatea Bio?
- Galatea Bio was founded by Carlos D. Bustamante in 2021.
- Who are Galatea Bio's investors?
- Galatea Bio's investors include CEI Ventures, Citta Capital, F-Prime Capital, Founder Collective, Function Ventures, Helios Digital Ventures, LifeX Ventures, Alexandria and 1 more.
- How much funding has Galatea Bio raised?
- Galatea Bio has disclosed $3.7M raised across 1 of its 2 known rounds.
- Where is Galatea Bio headquartered?
- Galatea Bio is headquartered in Miami Lakes, US.